0000000000417201

AUTHOR

Ellen Hoffmann

showing 3 related works from this author

Impact of Structural Heart Disease on the Acute Complication Rate in Atrial Fibrillation Ablation: Results from the German Ablation Registry

2013

Acute Complication Rate in AF Ablation Introduction Catheter ablation (CA) has emerged as a widespread therapeutic option in the treatment of atrial fibrillation (AF). Currently, no safety data with regard to the impact of the underlying structural heart diseases (SHD) are available. We sought to assess the risk for acute and long-term complications during CA of AF in relation to underlying SHD. Methods and Results We included 6,211 patients in a prospective registry undergoing CA of AF in 41 nationwide centers. All patients were divided into 4 groups according to the underlying heart disease: No SHD (69.4%), hypertensive heart disease (HHD) (12.0%), coronary artery disease (CAD) (15.1%), a…

medicine.medical_specialtyUnivariate analysisHeart diseasebusiness.industrymedicine.medical_treatmentCardiomyopathyAtrial fibrillationCatheter ablationOdds ratiomedicine.diseaseHypertensive heart diseaseCoronary artery diseasePhysiology (medical)Internal medicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessJournal of Cardiovascular Electrophysiology
researchProduct

Complication Rates of Catheter Ablation of Atrial Fibrillation in Patients Aged ≥75 Years versus <75 Years-Results from the German Ablation Regist…

2017

Age-Related Complication Rates in AF AblationIntroduction Despite a rising demand for catheter ablation (CA) of atrial fibrillation (AF) in an elderly population, complication and success rates are not fully elucidated. We sought to compare complication rates of CA of AF in patients ≥75 versus <75 years of age. Methods and Results Patients with symptomatic, drug-refractory AF were prospectively enrolled from January 2007 to 2010 in this multicenter study. A total of 4,449 patients, group 1 ≥75 years and group 2 <75 years (n = 227, age 77.3 ± 2.2 vs. 59.7 ± 9.8 years, 52.0% vs. n = 4,222, 68.9% male, CHA2DS2-VASc-Score 3.7 ± 1.0 vs. 1.7 ± 1.2; P < 0.001, respectively), with paroxysmal AF (59…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCatheter ablationAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseAblationSurgery03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineCohortmedicineCardiologyIn patient030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessComplicationStrokeJournal of Cardiovascular Electrophysiology
researchProduct

Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study

2010

Aims Gold electrodes have the theoretical advantage of creating bigger lesions than platinum–iridium (Pt–Ir) electrodes. We performed a prospective randomized study to compare the clinical efficacy of standard 8 mm Pt–Ir tip catheter (control) and 8 mm gold-tip catheters in the ablation of the cavotricuspid isthmus (CTI)-dependent atrial flutter. Methods and results A total of 463 patients undergoing CTI ablation in 19 clinical centres were randomized to receive the treatment by gold-tip or control catheter. The primary endpoint was cumulative radiofrequency (RF) application duration until achieving bidirectional CTI block. It did not differ significantly for the two catheters. The gold-tip…

MaleCavotricuspid isthmusmedicine.medical_specialtymedicine.medical_treatmentCatheter ablation030204 cardiovascular system & hematologyIridium03 medical and health sciences0302 clinical medicineRecurrencePhysiology (medical)medicineHumansFluoroscopyProspective Studies030212 general & internal medicineClinical efficacyElectrodesAgedPlatinumRetrospective Studiesmedicine.diagnostic_testbusiness.industryThermal ConductivityMiddle AgedAblationmedicine.disease3. Good healthSurgeryCatheterTreatment OutcomeAtrial FlutterCatheter AblationFemaleGoldCardiology and Cardiovascular MedicinebusinessAtrial flutterFollow-Up StudiesTip catheterEuropace
researchProduct